Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Lissencephaly patients are born with severe brain malformations and suffer from recurrent seizures. LIS1, the gene mutated in isolated lissencephaly patients, is a subunit of the heterotrimeric cytosolic enzyme platelet-activating factor acetylhydrolase (PAF-AH), interacts with tubulin, and affects microtubule dynamics. In order to gain molecular insights into the possible involvement of LIS1 in seizures in lissencephaly patients, we induced seizures in rats by injection of kainate. PAF-AH activity was markedly reduced as early as 30 min following initiation of seizures, making this parameter a sensitive indicator of seizure events. PAF-AH activity returned to and surpassed control values 1 week following initiation of seizures. Expression of LIS1 in the dentate gyrus changed significantly in a manner similar to that of PAF-AH enzymatic activity. This is the first correlation found between LIS1 expression and PAF-AH activity. Furthermore, the expression of the alpha2 catalytic subunit, which is the major PAF-AH catalytic subunit in rat adult brain, changed in a dramatic fashion. An additional higher-mobility LIS1 cross-reactive band was detected in samples isolated a week following seizure occurrence. This LIS1 isoform was enriched in the microtubule-associated fraction. We propose that LIS1 expression is an important factor in regulation of PAF-AH activity. We postulate that reductions in LIS1 protein levels found in lissencephaly patients may render them more susceptible to seizures.
Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel.
O
O
Shmueli
A
A
Cahana
O
O
Reiner
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000818:Animals; D000906:Antibodies; D002458:Cell Fractionation; D018891:Dentate Gyrus / Q000201:enzymology* / Q000254:growth & development / Q000503:physiopathology; D018690:Excitatory Amino Acid Agonists; D005625:Frontal Lobe / Q000201:enzymology / Q000254:growth & development / Q000503:physiopathology; D007608:Kainic Acid; D008297:Male; D008869:Microtubule-Associated Proteins / Q000032:analysis / Q000378:metabolism; D010741:Phospholipases A / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D011506:Proteins / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013226:Status Epilepticus / Q000139:chemically induced / Q000378:metabolism*
D000906:Antibodies; D018690:Excitatory Amino Acid Agonists; D008869:Microtubule-Associated Proteins; D010972:Platelet Activating Factor; D011506:Proteins; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D007608:Kainic Acid